This is a working overview of GLP-1 receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Arby's promoted their announcement by breaking two Guinness World Records. The first record, "world's smallest advertisement", measured 38.3 microns by 19.2 microns on a sesame seed and was printed at Georgia Tech. The second record, "largest advertising poster", took up approximately 5 acres of land and was placed in Monowi, Nebraska, America's smallest town. Toasted Subs, sandwiches served on a toasted ciabatta roll, were first introduced in September 2007. The initial line-up included the French Dip & Swiss Toasted Sub, Philly Beef Toasted Sub, Classic Italian Toasted Sub, and Turkey Bacon Club. Three months later, the Toasted Subs product line was extended to include the Meatball Toasted Sub and the Chicken Parmesan Toasted Sub. In October 2013, Arby's introduced a Smokehouse Brisket sandwich. In September 2014, Arby's introduced gyros to its menu for a limited time. Gyros were previously offered in 2006. They have since become a permanent menu fixture on the menu in April 2016. On an almost annual basis, Arby's had offered some sort of a flatbread melt sandwich for a limited time. In 2007 and again in 2008, it was the Philly Cheesesteak and the Fajita Beef. The Beef Fajita returned with the new Chicken Fajita in 2009. After a six-year hiatus, Steak Fajita Flatbreads were offered for a limited time in 2015. The following year, Steak Fajita returned in 2016 with Chicken Fajita along with a choice between a hot and mild sauce. After a nine-year hiatus, a pork-beef mixture meatball sandwich was reintroduced in July 2016.
military states that one of its soldiers was killed and another soldier was slightly wounded in north of Iraq the previous day, "during a controlled detonation of unexploded ordnance from a downed Iranian one-way attack drone." 2026 FIFA World Cup final: Spain beat defending champions Argentina 1–0 after extra time at the MetLife Stadium in East Rutherford, New Jersey to win a second FIFA World Cup title. July 20 – 2026 Iran war: The U.S. military conducts a ninth consecutive night of strikes on Iranian targets, which President Trump says are retaliation for the deaths of three American soldiers. July 21 The US announces a trade agreement with Jordan. The US begins allowing direct flights between the US and Lebanon for the first time since 1985. OpenAI reveals that an autonomous artificial intelligence agent powered by its models escaped a controlled testing environment and compromised the computer systems of Hugging Face while attempting to obtain answers to a cybersecurity evaluation. OpenAI describes it as an "unprecedented cyber incident". July 22 2026 Iran war: The US conducts its 11th consecutive night of strikes in Iran. Trump states that the US would strike and destroy Iran's bridges and power plants for each ship it attacks in the Strait of Hormuz. The U.S. signs a deal with Saudi Arabia to develop a civilian nuclear program in the country. Trump demands that Saudi Arabia join the Abraham Accords so that the agreement will take effect. July 23 2026 Iran war: The US conducts its 12th consecutive night of strikes in Iran.
=== Valve === Faliszek's and Wolpaw's writings led to them being hired by Valve circa 2005. Along with Wolpaw and Marc Laidlaw, Faliszek helped to create the storylines for the Half-Life and Portal series, along with having personally written the story for Left 4 Dead. He was also involved with Valve's work in virtual reality (VR) through the HTC Vive. In May 2017, Faliszek announced that after twelve years with Valve, he had left the company earlier in the year to work on unannounced projects.
===== Triple combination ===== The combination of metformin with dapagliflozin and saxagliptin is available in the United States as Qternmet XR. The combination of metformin with pioglitazone and glibenclamide is available in India as Accuglim-MP, Adglim MP, and Alnamet-GP; and in the Philippines as Tri-Senza. The combination of metformin with pioglitazone and lipoic acid is available in Turkey as Pional.
This means that substitution models can be viewed as implying a specific multinomial distribution for site pattern frequencies. If we consider a multiple sequence alignment of four DNA sequences there are 256 possible site patterns so there are 255 degrees of freedom for the site pattern frequencies. However, it is possible to specify the expected site pattern frequencies using five degrees of freedom if using the Jukes-Cantor model of DNA evolution, which is a simple substitution model that allows one to calculate the expected site pattern frequencies only the tree topology and the branch lengths (given four taxa an unrooted bifurcating tree has five branch lengths). Substitution models also make it possible to simulate sequence data using Monte Carlo methods. Simulated multiple sequence alignments can be used to assess the performance of phylogenetic methods and generate the null distribution for certain statistical tests in the fields of molecular evolution and molecular phylogenetics. Examples of these tests include tests of model fit and the "SOWH test" that can be used to examine tree topologies.
Sources: en.wikipedia.org
United States: The U.S. government operates border preclearance facilities at several ports and airports in foreign territory. They are staffed and operated by U.S. Customs and Border Protection officers. Travellers pass through the U.S. Immigration and Customs, Public Health, and Agriculture inspections before boarding their aircraft, ship, or train. This process is intended to streamline border procedures, reduce congestion at ports of entry, and facilitate travel between the preclearance location and American airports that are not equipped to handle international travellers. These facilities are present at the majority of major Canadian airports, as well as selected airports in Bermuda, Aruba, the Bahamas, Abu Dhabi and Ireland. Facilities located in Canada accept NEXUS cards and United States Passport cards (land/sea entry only) in place of passports. A preclearance facility is currently being planned at Dubai International Airport. Citizens of the Bahamas who enter United States through either of the two preclearance facilities in that country enjoy an exemption from the general requirement to hold a visa as long as they can sufficiently prove that they do not have a significant criminal record in either the Bahamas or the U.S. All Bahamians applying for admission at a port-of-entry other than the preclearance facilities located in Nassau or Freeport International airports are required to have a valid visa. Preclearance facilities are also operated at Pacific Central Station, the Port of Vancouver, and the Port of Victoria in British Columbia.
Compulsion Games said they were prepared to offer refunds even to Kickstarter backers from Australia should they be unable to achieve a rating. The Australian Ratings Board agreed to review their classification, offering interested parties to also reply in standing for reclassification of the game during the month of July 2018. On 3 July, the Board announced that they had reclassified We Happy Few with an R18+ rating, still warning consumers of its drug-use mechanic, but otherwise clearing the title to be sold within Australia. The full game was released for PlayStation 4, Windows, and Xbox One on 10 August 2018. On 27 November 2018, Dark Horse Comics released a 192-page book titled The Art of We Happy Few.
== Research == Diazoxide was under development by Lakatos-Topol and Proanagen as a topical solution for the treatment of androgenic alopecia (pattern hair loss) and alopecia areata in the 1980s but was ultimately never marketed. It was intended as a competitor and alternative to minoxidil (Rogaine) for such purposes. The drug applied topically was found to promote scalp hair growth in balding stump-tailed macaques. Under the name Vykat XR, diazoxide choline is an approved therapy for Prader-Willi syndrome and is under investigation for monogenic obesity caused by mutations in the SH2B1, PCSK1, or SIM1 genes.
== History == Planet Half-Life ran from April 27, 1999 to August 13, 2012. Since then, it had undergone numerous format changes, both in content and aesthetic. The following is a timeline of major changes and other events.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.